(Adds details on Mexico unit, CEO and analysts' comments; updates share movement)
(Corrects paragraph three to say profit per customer rose 50 percent to 21 pounds in Mexico business, not doubled in whole company)
reducing the progression of idiopathic pulmonary fibrosis ( IPF ) or mortality. " IPF is an irreversible and ultimately fatal disease characterized ..... ability of lungs to absorb oxygen," InterMune explains. IPF 's five-year survival rate is 20-40%. Pirfenidone
By Henry Nyce : On July 17, 2013 I wrote an article on 2 foreign banks that are in a great position to grow with expansion of the Panama Canal. The 2 banks are The Bank of Nova Scotia ( BNS ), now called Scotiabank, and Banco Latinoamericano de Comercio Exterior, S.A. ( BLX ), often referred to as
trading today. In totally these ETFs each had at least 3 years of trading, with PXN launching in 2005, but together had only $67 million in total assets. Related ETFs: PDP , QUAL , PWO , SIZE , IPF , IXG , AXFN , GAF Post your comment!
Esbriet has demonstrated solidly good efficacy results in previous clinical trials. With zero drugs treating the chronic and fatal IPF on the market, the benefit Esbriet provides to patients is an automatic improvement over the current situation, Complete Story
By Pater Tenebrarum : European Exposure to Emerging Markets Ever since the sovereign debt crisis in Europe has retreated into the background, worries about European banks have quieted down as well. However, the recent EM currency crisis may bring them to the fore again. According to a recent ...
sector that he views as adversarial.” Related ETFs: XLF , FAS , FAZ , UYG , KRE , VFH , KBE , PSP , IYF , EUFN , IAI , KIE , IPF , IAT , SEF , IYG , IAK , PFI , FXO , IXG , KBWB , PEX , KME , RKH , QABA , FINU , KCE , KRU , RWW , KBWR , FNCL , RYF , KBWI
lead drug candidate is designed to combat IPF , a disease for which there are currently ..... drug designation for the treatment of IPF from the FDA, conferring a seven-year ..... approval for idiopathic pulmonary fibrosis, or IPF . Given InterMune’s past clinical and regulatory
Phase III ASCEND study in idiopathic pulmonary fibrosis, or IPF --which are expected early next quarter and are necessary for ..... reporting the results of its two Phase III trials for BIBF-1120 in IPF in early 2014, which, if positive, could add competition to